Thermostable cross-protective subunit vaccine against Brucella species

Clinical and Vaccine Immunology

Volumn 21, Issue 12, 2014, Pages 1681-1688

  Cherwonogrodzky, John W ^a   Barabé, Nicole D ^a   Grigat, Michelle L ^a   Lee, William E ^a   Poirier, Robert T ^a   Jager, Scott J ^a   Berger, Bradley J ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; BRUCELLA VACCINE; LIVE VACCINE; SUBUNIT VACCINE;

ANIMAL; BLOOD; BRUCELLA; BRUCELLOSIS; DISEASE MODEL; FEMALE; IMMUNOLOGY; MOUSE; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BRUCELLA; BRUCELLA VACCINE; BRUCELLOSIS; DISEASE MODELS, ANIMAL; FEMALE; MICE; VACCINATION; VACCINES, ATTENUATED; VACCINES, SUBUNIT;

EID: 84914166006     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00447-14     Document Type: Article

References (43)

1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. 2006. The new global map of human brucellosis. Lancet Infect. Dis. 6:91-99. http://dx.doi.org/10.1016/S1473-3099(06)70382-6.
2. Domaradskij IV, Orent W. 2006. Achievements of the Soviet biological weapons programme and implications for the future. Rev. Sci. Tech. Off. Int. Epiz. 25:153-161.
3. Pappas G, Panagopoulou P, Christou L, Akritidis N. 2006. Brucella as a biological weapon. Cell. Mol. Life Sci. 63:2229-2236. http://dx.doi.org/10.1007/s00018-006-6311-4.
4. Doganay GD, Doganay M. 2013. Brucella as a potential agent of bioterrorism. Recent Pat. Antiinfect. Drug Discov. 8:27-33. http://dx.doi.org/10.2174/1574891X11308010006.
5. Mableson HE, Okello A, Picozzi K, Welburn SC. 2014. Neglected zoonotic diseases-the long and winding road to advocacy. PLoS Negl. Trop. Dis. 8(6):e2800. http://dx.doi.org/10.1371/journal.pntd.0002800.
6. Williams E. 1988. Brucellosis in humans: its diagnosis and treatment. APMIS Suppl. 3:21-25.
7. Ficht TA, Kahl-McDonagh MM, Arenas-Gambos AM, Rice-Ficht AC. 2009. Brucellosis: the case for live, attenuated vaccines. Vaccine 27(Suppl 4):D40-D43. http://dx.doi.org/10.1016/j.vaccine.2009.08.058.
8. Chen D, Kristensen D. 2009. Opportunities and challenges of developing thermostable vacines. Expert Rev. Vaccines 8:547-557. http://dx.doi.org/10.1586/erv.09.20.
9. Cherwonogrodzky JW, Di Ninno VL. 1995. A polysaccharide vaccine to enhance immunity against brucellosis. Arch. Med. Vet. (Chile)27:29-37.
10. Cherwonogrodzky JW, Wong JP, Di Ninno VL, Lord VR, Marino OC. 1996. A polysaccharide vaccine to enhance immunity against Brucella species, abstr 101.019, p 233. Abstr. Int. Congr. Infect. Dis.
11. Lord VR, Cherwonogrodzky JW, Schurig GG, Lord RD, Marcano MJ, Meléndez GE. 1998. Venezuelan field trials of vaccines against brucellosis in swine. Am J. Vet. Res. 59:546-551.
12. Asbakk K, Gall D, Stuen S. 1999. A screening ELISA for brucellosis in reindeer. Zentralbl. Veterinarmed. B 46:649-657.
13. Bundle DR, Cherwonogrodzky JW, Perry MB. 1987. Structural elucidation of the Brucella melitensis M antigen by high-resolution NMR at 500 MHz. Biochemistry 26:8717-8726. http://dx.doi.org/10.1021/bi00400a034.
14. Avila-Calderon ED, Lopez-Merino A, Jain N, Peralta H, Lopez-Villegas EO, Sriranganathan N, Boyle SM, Witonsky S, Contreras-Rodriguez A. 2012. Characterization of outer membrane vesicles from Brucella melitensis and protection induced in mice. Clin. Dev. Immunol. 2012:352493. http://dx.doi.org/10.1155/2012/352493.
15. Caroff M, Bundle DR, Perry MB, Cherwonogrodzky JW, Duncan JR. 1984. Antigenic S-type lipopolysaccharide of Brucella abortus 1119-3. Infect Immun. 46:384-388.
16. Masuko T, Minami A, Iwasaki N, Majima T, Nishimura S-I, Lee YC. 2005. Carbohydrate analysis by a phenol-sulfuric acid method in microplate format. Anal. Biochem. 339:69-72. http://dx.doi.org/10.1016/j.ab.2004.12.001.
17. Cherwonogrodzky JW, Dubray G, Moreno E, Mayer H. 1990. Antigens of Brucella, p 19-64. In Nielsen K, Duncan JR (ed), Animal brucellosis. CRC Press, Boca Raton, FL.
18. Lee CH, Tsai CM. 1999. Quantification of bacterial lipopolysaccharides by the Purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. Anal. Biochem. 267:161-168. http://dx.doi.org/10.1006/abio.1998.2961.
19. Berti F, Adamo R. 2013. Recent mechanistic insights on glycoconjugate vaccines and future perspectives. ACS Chem. Biol. 8:1653-1663. http://dx.doi.org/10.1021/cb400423g.
20. Anwar E, Goldberg E, Fraser A, Acosta CJ, Paul M, Leibovici L. 2014. Vaccines for preventing typhoid fever. Cochrane Database Syst. Rev. 1:CD001261. http://dx.doi.org/10.1002/14651858.CD001261.pub3.
21. Thiem VD, Lin FYC, Canh DG, Son NH, Anh DD, Mao ND, Chu C, Hunt SW, Robbins JB, Shneerson R, Szu SC. 2011. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG Anti-Vi, and is compatible with routine infant vaccines. Clin. Vaccine Immunol. 18:730-735. http://dx.doi.org/10.1128/CVI.00532-10.
22. Kuberan B, Linhardt RJ. 2000. Carbohydrate based vaccines. Curr. Org. Chem. 4:653-677. http://dx.doi.org/10.2174/1385272003376111.
23. Zygmunt MS, Dubray G, Bundle DR, Perry MP. 1988. Purified native haptens of Brucella abortus B19 and B. melitensis 16M reveal the lipopoly-saccharide origin of the antigens. Ann. Inst. Pasteur Microbiol. 139:421-433.
24. Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, Shlomchik MJ, Vogel SN. 2009. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc. Natl. Acad. Sci. U. S. A. 106:4343-4348. http://dx.doi.org/10.1073/pnas.0813411106.
25. Nielsen K, Smith P, Yu W, Nicoletti P, Jungersen G, Stack J, Godfroid J. 2006. Serological discrimination by indirect enzyme immunoassay between the antibody response to Brucella sp. and Yersinia enterocolitica O:9 in cattle and pigs. Vet. Immunol. Immunopathol. 109:69-78. http://dx.doi.org/10.1016/j.vetimm.2005.07.025.
26. Wilson GS, Miles AA. 1948. Topley and Wilson's principles of bacteriology and immunity, 3rd ed, vol 1, p 825, 833, 834. Edward Arnold & Co., London, United Kingdom.
27. Zaccheus MV, Ali T, Cloeckaert A, Zygmunt MS, Wintraub A, Iriarte M, Moriyón I, Widmalm G. 2013. The epitopic and structural characterization of Brucella suis biovar 2 O-polysaccharide demonstrates the existence of a new M-negative C-negative smooth Brucella serovar. PLoS One 8:e53941. http://dx.doi.org/10.1371/journal.pone.0053941.
28. Zygmunt MS, Jacques I, Bernardet N, Cloeckaert A. 2012. Lipopolysaccharide heterogeneity in the atypical group of novel emerging Brucella species. Clin. Vaccine Immunol. 19:1370-1373. http://dx.doi.org/10.1128/CVI.00300-12.
29. Institute of Medicine. 2001. CDC anthrax vaccine safety and efficacy research program: interim report, p 14. National Academies Press, Washington, DC.
30. Guiard J, Paszkiewicz E, Dadowska J, Bundle DR. 2013. Design and synthesis of a universal antigen to detect brucellosis. Angew Chem. Int. Ed. Engl. 52:1-6. http://dx.doi.org/10.1002/anie.201209858.
31. Monreal D, Grilló MJ, González D, Marin CM, De Miguel MJ, López-Goñi I, Blasco JM, Cloeckaert A, Moriyón I. 2003. Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model. Infect. Immun. 71:3261-3271. http://dx.doi.org/10.1128/IAI.71.6.3261-3271.2003.
32. Aparicio ED. 2013. Epidemiology of brucellosis in domestic animals caused by Brucella melitensis, Brucella suis and Brucella abortus. Rev. Sci. Tech. Off. Int. Epiz. 32:53-60.
33. Staszkiewicz J, Lewis CM, Colville J, Zervos M, Band J. 1991. Outbreak of Brucella melitensis among microbiology laboratory workers in a community hospital. J. Clin. Microbiol. 29:287-290.
34. Farrell ID, Robertson L, Hinchliffe PM. 1975. Serum antibody response in acute brucellosis. J. Hyg. Camb. 74:23-28.
35. Cherwonogrodzky JW, Nielsen KH. 1988. Brucella abortus 1119-3 Ochain polysaccharide to differentiate sera from B. abortus S-19-vaccinated and field-strain-infected cattle by agar gel immunodiffusion. J. Clin Microbiol. 26:1120-1123.
36. Gu W, Gu D, Yuan Y, Hamit T. 1993. Research on anti-idiotypic antibodies to bovine abortus. Wei Sheng Wu Xue Bao 33:378-382.
37. Yumuk Z, Afacan G, Caliskan S, Irvem A, Arslan U. 2007. Relevance of autoantibody detection to the rapid diagnosis of brucellosis. Diagn. Microbiol. Infect. Dis. 58:271-273. http://dx.doi.org/10.1016/j.diagmicrobio.2007.01.003.
38. Baldwin CL, Goenka R. 2006. Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection? Crit. Rev. Immunol. 26:407-442. http://dx.doi.org/10.1615/CritRevImmunol.v26.i5.30.
39. Skendros P, Boura P. 2013. Immunity to brucellosis. Rev. Sci. Tech. 32:137-147.
40. Gao L, Shang S, Zhang C, Tong M, Chen Y. 2013. Lower mannosebinding lectin contributes to deleterious H1N1 2009 infection in children. APMIS 122:136-139. http://dx.doi.org/10.1111/apm.12111.
41. Niyonsaba F, Nagaoka I, Ogawa H. 2006. Human defensins and cathelicidins in the skin:beyonddirect antimicrobial properties. Crit.Rev.Immunol.26:545-576. http://dx.doi.org/10.1615/CritRevImmunol.v26.i6.60.
42. Ishag HZ, Li C, Huang L, Sun MX, Wang F, Ni B, Malik T, Chen PY, Mao X. 2013. Griffithsin inhibits Japanese encephalitis virus infection in vitro and in vivo. Arch. Virol. 158:349-358. http://dx.doi.org/10.1007/s00705-012-1489-2.
43. Viriyakosol S, Jimenez Mdel P, Gurney MA, Ashbaugh ME, Fierer J. 2013. Dectin-1 is required for resistance to coccidioidomycosis in mice. mBio 4(1):e00597-12. http://dx.doi.org/10.1128/mBio.00597-12.